Cowen & Co. Remains a Buy on Acorda Therapeutics (ACOR)

By Jason Carr

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Acorda Therapeutics (ACORResearch Report), with a price target of $10.00. The company’s shares closed last Monday at $2.12, close to its 52-week low of $1.49.

According to, Nadeau is a 5-star analyst with an average return of 9.0% and a 53.2% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Acorda Therapeutics with a $6.17 average price target.

See today’s analyst top recommended stocks >>

Based on Acorda Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $264 million. In comparison, last year the company had a net profit of $9.6 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.